Amelioration of relapsing polychondritis in a child treated with oral collagen

M. J. Navarro, G. C. Higgins, K. M. Lohr, Linda Myers

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Relapsing polychondritis (RP) is a disease characterized by inflammation and the destruction of cartilage. The detection of antibodies to native type II collagen (CII) in the sera of some patients with relapsing polychondritis suggests that autoimmunity to this cartilage specific protein plays a role in the pathogenesis of the disease. RP is so rare that controlled therapeutic trials have not been carried out. We describe herein a child with RP who had amelioration of symptoms and a deviation in the cellular immune response to CII after being treated with daily oral CII as a toleragen.

Original languageEnglish (US)
Pages (from-to)101-103
Number of pages3
JournalAmerican Journal of the Medical Sciences
Volume324
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Relapsing Polychondritis
Collagen
Cartilage
Collagen Type II
Autoimmunity
Cellular Immunity
Inflammation
Antibodies
Serum
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Amelioration of relapsing polychondritis in a child treated with oral collagen. / Navarro, M. J.; Higgins, G. C.; Lohr, K. M.; Myers, Linda.

In: American Journal of the Medical Sciences, Vol. 324, No. 2, 01.01.2002, p. 101-103.

Research output: Contribution to journalArticle

Navarro, M. J. ; Higgins, G. C. ; Lohr, K. M. ; Myers, Linda. / Amelioration of relapsing polychondritis in a child treated with oral collagen. In: American Journal of the Medical Sciences. 2002 ; Vol. 324, No. 2. pp. 101-103.
@article{940768ce439b4caaa0e331f7d4da068a,
title = "Amelioration of relapsing polychondritis in a child treated with oral collagen",
abstract = "Relapsing polychondritis (RP) is a disease characterized by inflammation and the destruction of cartilage. The detection of antibodies to native type II collagen (CII) in the sera of some patients with relapsing polychondritis suggests that autoimmunity to this cartilage specific protein plays a role in the pathogenesis of the disease. RP is so rare that controlled therapeutic trials have not been carried out. We describe herein a child with RP who had amelioration of symptoms and a deviation in the cellular immune response to CII after being treated with daily oral CII as a toleragen.",
author = "Navarro, {M. J.} and Higgins, {G. C.} and Lohr, {K. M.} and Linda Myers",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00000441-200208000-00009",
language = "English (US)",
volume = "324",
pages = "101--103",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Amelioration of relapsing polychondritis in a child treated with oral collagen

AU - Navarro, M. J.

AU - Higgins, G. C.

AU - Lohr, K. M.

AU - Myers, Linda

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Relapsing polychondritis (RP) is a disease characterized by inflammation and the destruction of cartilage. The detection of antibodies to native type II collagen (CII) in the sera of some patients with relapsing polychondritis suggests that autoimmunity to this cartilage specific protein plays a role in the pathogenesis of the disease. RP is so rare that controlled therapeutic trials have not been carried out. We describe herein a child with RP who had amelioration of symptoms and a deviation in the cellular immune response to CII after being treated with daily oral CII as a toleragen.

AB - Relapsing polychondritis (RP) is a disease characterized by inflammation and the destruction of cartilage. The detection of antibodies to native type II collagen (CII) in the sera of some patients with relapsing polychondritis suggests that autoimmunity to this cartilage specific protein plays a role in the pathogenesis of the disease. RP is so rare that controlled therapeutic trials have not been carried out. We describe herein a child with RP who had amelioration of symptoms and a deviation in the cellular immune response to CII after being treated with daily oral CII as a toleragen.

UR - http://www.scopus.com/inward/record.url?scp=0036322148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036322148&partnerID=8YFLogxK

U2 - 10.1097/00000441-200208000-00009

DO - 10.1097/00000441-200208000-00009

M3 - Article

VL - 324

SP - 101

EP - 103

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 2

ER -